Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Income towards Parent Company: 2020-2024

Historic Income towards Parent Company for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to -$140.0 million.

  • Arcutis Biotherapeutics' Income towards Parent Company rose 117.84% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.3 million, marking a year-over-year increase of 77.33%. This contributed to the annual value of -$140.0 million for FY2024, which is 46.58% up from last year.
  • Arcutis Biotherapeutics' Income towards Parent Company amounted to -$140.0 million in FY2024, which was up 46.58% from -$262.1 million recorded in FY2023.
  • Arcutis Biotherapeutics' 5-year Income towards Parent Company high stood at -$136.6 million for FY2020, and its period low was -$311.5 million during FY2022.
  • For the 3-year period, Arcutis Biotherapeutics' Income towards Parent Company averaged around -$237.9 million, with its median value being -$262.1 million (2023).
  • In the last 5 years, Arcutis Biotherapeutics' Income towards Parent Company plummeted by 51.02% in 2021 and then surged by 46.58% in 2024.
  • Over the past 5 years, Arcutis Biotherapeutics' Income towards Parent Company (Yearly) stood at -$136.6 million in 2020, then tumbled by 51.02% to -$206.4 million in 2021, then tumbled by 50.93% to -$311.5 million in 2022, then increased by 15.83% to -$262.1 million in 2023, then spiked by 46.58% to -$140.0 million in 2024.